August 26, 2015 07:57 AM Eastern Daylight Time
SAN DIEGO--(BUSINESS WIRE)--Allele Biotechnology & Pharmaceuticals Inc., a San Diego based life sciences company with a focus on novel technology development, releases the first group of a brand new class of antibodies against crucial biological targets to the research market. This week, Allele launches nano-antibodies isolated from llamas against human bFGF, P16, VEGF, and TNFa, which are all important targets in the field of cancer biology.
One World Lab entered an agreement with OriGene Technologies, Inc to become a global distributor of OriGene's antibody portfolio. "The addition of OriGene’s proprietary antibodies supports our strategy and broadens our portfolio to more than 75,000 unique antibodies. Researchers will have several thousand more antibodies to affordably sample, while knowing with confidence that each antibody is sourced from the original manufacturer and not re-labeled.Read more